Elite Pharmaceuticals Announces Launch of Generic Hydroxyzine Tablets
April 21, 2015 10:02 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., April 21, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP) today announced the launch of generic Hydroxyzine HCI 10 mg, 25 mg and 50 mg...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2015
February 17, 2015 17:56 ET
|
Elite Pharmaceuticals, Inc.
Revenues Increase 8.5% Over Prior Quarter
Conference Call Scheduled for Wednesday, February 18 at 11:00 AM EST
NORTHVALE, N.J., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc....
Elite Pharmaceuticals Provides Guidance on Phase III Study for ELI-200
February 17, 2015 17:55 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP) announced guidance today regarding the Company's Phase III trial for ELI-200, an...
Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, February 18, 2015
February 12, 2015 14:49 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals Announces First Shipment of Generic Isradipine Capsules
January 15, 2015 10:46 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 15, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the first shipments of generic Isradipine 2.5 mg and 5.0 mg...
Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
December 16, 2014 08:38 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the continued expansion of Elite's intellectual property...
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
December 03, 2014 09:55 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015
November 18, 2014 18:24 ET
|
Elite Pharmaceuticals, Inc.
Revenues increase by 8%
Conference Call Scheduled for Wednesday, November 19 at 11:00 AM EST
NORTHVALE, N.J., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the...
Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, November 19, 2014
November 13, 2014 17:02 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals Announces New Management Appointments
October 24, 2014 07:15 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Oct. 24, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP),a specialty pharmaceutical company developing a pipeline of abuse-deterrent...